| Primary |
| Tuberculosis |
56.1% |
| Pulmonary Tuberculosis |
17.8% |
| Lymph Node Tuberculosis |
3.2% |
| Staphylococcal Infection |
2.9% |
| Infection |
2.7% |
| Mycobacterium Avium Complex Infection |
1.6% |
| Postoperative Wound Infection |
1.6% |
| Disseminated Tuberculosis |
1.4% |
| Mycobacterium Ulcerans Infection |
1.4% |
| Osteomyelitis |
1.4% |
| Tuberculous Pleurisy |
1.4% |
| Bacterial Infection |
1.1% |
| Blood Pressure |
1.1% |
| Latent Tuberculosis |
1.1% |
| Antibiotic Therapy |
0.9% |
| Aspergillosis |
0.9% |
| Brucellosis |
0.9% |
| Infected Skin Ulcer |
0.9% |
| Localised Infection |
0.9% |
| Product Used For Unknown Indication |
0.9% |
|
| Hepatocellular Damage |
15.3% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
12.9% |
| Renal Failure Acute |
8.1% |
| Vomiting |
8.1% |
| Nausea |
6.5% |
| Pyrexia |
4.8% |
| Drug Interaction |
4.0% |
| Rash |
4.0% |
| Thrombocytopenia |
4.0% |
| Treatment Failure |
4.0% |
| Weight Decreased |
4.0% |
| Acute Hepatic Failure |
3.2% |
| General Physical Health Deterioration |
3.2% |
| Tubulointerstitial Nephritis |
3.2% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.4% |
| Jaundice |
2.4% |
| Myalgia |
2.4% |
| Paradoxical Drug Reaction |
2.4% |
| Product Quality Issue |
2.4% |
| Tuberculosis |
2.4% |
|
| Secondary |
| Tuberculosis |
28.3% |
| Product Used For Unknown Indication |
24.8% |
| Hiv Infection |
15.3% |
| Pulmonary Tuberculosis |
7.3% |
| Pneumonia |
3.5% |
| Disseminated Tuberculosis |
2.6% |
| Staphylococcal Infection |
2.5% |
| Prophylaxis |
2.3% |
| Drug Use For Unknown Indication |
2.1% |
| Pyrexia |
1.6% |
| Hypertension |
1.2% |
| Meningitis Tuberculous |
1.2% |
| Osteomyelitis |
1.2% |
| Bacteraemia |
1.0% |
| Atypical Mycobacterial Infection |
0.9% |
| Bacterial Infection |
0.9% |
| Diffuse Large B-cell Lymphoma |
0.9% |
| Aspergillosis |
0.8% |
| Cellulitis |
0.8% |
| Mycobacterium Avium Complex Infection |
0.8% |
|
| Vomiting |
11.9% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
10.4% |
| Deep Vein Thrombosis |
9.7% |
| Death |
8.2% |
| Hepatotoxicity |
6.7% |
| Neutropenia |
6.0% |
| Renal Failure Acute |
5.2% |
| Leukopenia |
3.7% |
| Nausea |
3.7% |
| Pyrexia |
3.7% |
| Tuberculosis |
3.7% |
| Drug Hypersensitivity |
3.0% |
| Hepatitis |
3.0% |
| Hypersensitivity |
3.0% |
| Rash |
3.0% |
| Renal Tubular Disorder |
3.0% |
| Sepsis |
3.0% |
| Sinus Tachycardia |
3.0% |
| Staphylococcal Infection |
3.0% |
| Thrombocytopenia |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
34.7% |
| Tuberculosis |
9.0% |
| Hiv Infection |
8.8% |
| Drug Use For Unknown Indication |
7.8% |
| Rheumatoid Arthritis |
4.8% |
| Pain |
4.0% |
| Prophylaxis |
3.5% |
| Hypertension |
3.3% |
| Multiple Myeloma |
3.1% |
| Staphylococcal Infection |
2.7% |
| Depression |
2.5% |
| Diabetes Mellitus |
2.4% |
| Crohn's Disease |
2.2% |
| Pulmonary Tuberculosis |
1.9% |
| Endocarditis |
1.8% |
| Nuclear Magnetic Resonance Imaging |
1.7% |
| Anxiety |
1.5% |
| Mycobacterium Avium Complex Infection |
1.5% |
| Gastrooesophageal Reflux Disease |
1.4% |
| Asthma |
1.2% |
|
| Vomiting |
11.8% |
| Weight Decreased |
10.9% |
| Death |
7.1% |
| Staphylococcal Infection |
6.7% |
| Pyrexia |
6.3% |
| Pain In Extremity |
5.9% |
| Tuberculosis |
5.0% |
| Drug Ineffective |
4.2% |
| Dyspnoea |
4.2% |
| Off Label Use |
3.8% |
| Urinary Tract Infection |
3.8% |
| Wound Infection Staphylococcal |
3.8% |
| Leukopenia |
3.4% |
| Rash |
3.4% |
| Renal Failure |
3.4% |
| Respiratory Failure |
3.4% |
| Tachycardia |
3.4% |
| Thrombocytopenia |
3.4% |
| Wound Drainage |
3.4% |
| Immune Reconstitution Syndrome |
2.9% |
|
| Interacting |
| Atypical Mycobacterial Infection |
19.2% |
| Product Used For Unknown Indication |
15.2% |
| Mycobacterium Avium Complex Infection |
14.4% |
| Immunosuppression |
10.4% |
| Pain |
5.6% |
| Tuberculosis |
5.6% |
| Endocarditis |
4.0% |
| Osteomyelitis Bacterial |
3.2% |
| Pain In Extremity |
3.2% |
| Renal Transplant |
3.2% |
| Staphylococcal Infection |
3.2% |
| Bronchopulmonary Aspergillosis |
1.6% |
| Brucellosis |
1.6% |
| Escherichia Bacteraemia |
1.6% |
| Hiv Infection |
1.6% |
| Liver Carcinoma |
1.6% |
| Systemic Candida |
1.6% |
| Type 2 Diabetes Mellitus |
1.6% |
| Depression |
0.8% |
| Drug Use For Unknown Indication |
0.8% |
|
| Drug Interaction |
13.6% |
| Cough |
9.1% |
| Dyspnoea |
9.1% |
| Inhibitory Drug Interaction |
9.1% |
| Weight Decreased |
9.1% |
| Diabetes Mellitus Inadequate Control |
4.5% |
| Drug Tolerance |
4.5% |
| International Normalised Ratio Decreased |
4.5% |
| Metabolic Acidosis |
4.5% |
| Pneumonia |
4.5% |
| Pulmonary Tuberculosis |
4.5% |
| Pyrexia |
4.5% |
| Staphylococcal Infection |
4.5% |
| Stevens-johnson Syndrome |
4.5% |
| Tuberculosis Gastrointestinal |
4.5% |
| Vomiting |
4.5% |
|
